+91-8668442535

Devic's Syndrome Treatment Market By Type Of Drugs (Eculizumab, Methylprednisolone, Azathioprine, Mycophenolate Mofetil, Rituximab) - Growth, Future Prospects, And Competitive Analysis, 2019 - 2027

Industry Outlook

Devic's syndrome (neuromyelitis optica) treatment accounted for a market value of US$ 156.8 million in 2018 and is projected to grow at a CAGR of 12.0% during the forecast period from 2019 to 2027. Devic's disease, or neuromyelitis optics, is an autoimmune disease in which antibodies and immune system cells mainly damage the optic nerves and the spinal cord but, in a few cases, also affect the brain. The injury to the optical nerves leads to inflammation and soreness, leading to vision loss and pain; the injury to the spinal cord leads to paralysis in the arms or legs, loss of sensation, and problems with bladder and bowel function. The key factors responsible for the growth of the global Devic's syndrome treatment market are rising awareness and prevalence related to orphan diseases, the recent launch of the first-target-specific drug Soliris (Eculizumab), and a strong drug pipeline expected to provide significant growth in the market.

Soliris (eculizumab) will aid the significant growth of the Devic's Syndrome treatment market throughout the forecast period.

Soliris (eculizumab) is a terminal complement inhibitor owned by Alexion. Soliris works by specifically preventing the activation of particular proteins in the complement system (C5a and C5b), which play a role in the treatment of Devic's syndrome. Patients suffering from Devic's syndrome possess AQP4 antibodies, and the body's immune system can turn against itself to produce autoantibodies against AQP4. Activation of anti-AQP4 autoantibodies leads to damage to vital cells in the CNS, assisting further demyelination and the death of neurons, primarily in the optic nerve and spinal cord. There are three promising molecules in the Devic's syndrome treatment pipeline, such as natalizumab (Phase 3; Hoffmann-La Roche/Chugai Pharmaceutical), MEDI-551 (Phase 2/3; MedImmune LLC), and RC18 (Phase 3; RemeGen, Ltd.). Chugai Pharmaceutical launched Phase 2 results related to Satralizumab on October 15, 2018; it is an investigational humanized anti-IL-6 receptor recycling monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).

North America dominated the overall global market specifically due to recent drug approvals, promising drugs in the pipeline, and a developed diagnostic landscape.

In 2018, North America dominated the market and was anticipated to retain its position throughout the forecast period due to high awareness related to orphan diseases, rising requirements for target-specific molecules to treat Devic's Syndrome, and easy adaptability and accessibility for newly launched drugs. According to the National Multiple Sclerosis Society, there are around 4,000 people suffering from Devic's syndrome in the United States, with a majority of women. Asia Pacific will grow during the forecast period from 2019 to 2027 due to increasing awareness related to Devic's Syndrome, which will assist in the rise in diagnosis and treatment rates among patients suffering from rare diseases.

Historical and Forecast Period

The Devic's Syndrome treatment market was analyzed considering current market trends for the base year of 2018, and based on future trends, CAGRs were calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

This report comprises in-depth information related to the Devic's Syndrome treatment market, along with major factors affecting or assisting the market, such as opportunities, drivers, and restraints. A descriptive analysis covering market drivers, challenges, and opportunities is provided specifically for country-level and regional segmentation. This report covered detailed information related to the global Devic's syndrome treatment market, segmented based on drug type and geography. The report also includes a pipeline analysis of upcoming drugs and a competitive analysis of the major companies present in the Devic's Syndrome treatment market, including detailed data related to the competitive landscape of the market and the recent market strategies and product pipeline.

The major companies involved in the Devic's Syndrome treatment industry were studied based on financial data, product portfolios, current press releases, and key market strategies. This report also covers attractive investment propositions analyzed based on an exclusive geographical PESTEL analysis. Major companies included in the report are Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidiary of Pfizer), Mylan Pharmaceuticals, Inc., Chugai Pharmaceutical, MedImmune LLC, and RemeGen, Ltd., among others.

Key questions are answered in this report.

  • Which is the most desired drug used to manage and treat Devic's syndrome, and why?
  • What are the recent market strategies followed by the key companies and the competitive landscape of the Devic's syndrome treatment market?
  • Which are the current and future key geographical markets (regions and countries) in Devic's syndrome treatment?
  • Which is the fastest and largest growing Devic's syndrome treatment segment globally?
  • What are the drivers, restraints, and opportunities in the Devic's syndrome treatment market?

Frequently Asked Questions:

The market for Devic's Syndrome Treatment Market is expected to reach US$ 156.8 Mn by 2027.

The Devic's Syndrome Treatment Market is expected to see significant CAGR growth over the coming years, at 12.0%.

The report is forecasted from 2019-2027.

The base year of this report is 2018.

Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidiary of Pfizer), Mylan Pharmaceuticals, Inc., Chugai Pharmaceutical, MedImmune LLC, and RemeGen, Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jul 2019
Category:  Pharmaceuticals
Report ID:   59801
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support